| Overview |
| bsm-62939r-pe-cy3 |
| Phospho-POLR2A (Ser2) Recombinant Monoclonal Antibody, PE-Cy3 Conjugated |
| WB, FCM |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human POLR2A around the phosphorylation site of S2 |
| Ser2 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5430 |
| P24928 |
| Nucleus |
| POLR2A; POLR2; RNA polymerase II CTD repeat YSPTSPS. |
| During transcription elongation, Pol II moves on the template as the transcript elongates. Elongation is influenced by the phosphorylation status of the C-terminal domain (CTD) of Pol II largest subunit (RPB1), which serves as a platform for assembly of factors that regulate transcription initiation, elongation, termination and mRNA processing. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz